On this page of StockholderLetter.com we present the 4/10/2023 shareholder letter from iSpecimen Inc. — ticker symbol ISPC. Reading current and past ISPC letters to shareholders can bring important insights into the investment thesis.

 •  4/10/2023 Letter Continued (Full PDF)
 •  6/10/2024 ISPC Stockholder Letter
 •  ISPC Benford's Law Stock Score = 89

ISPC 4/10/2023 Shareholder/Stockholder Letter Transcript:

Transforming
Biospecimen
Procurement
An online marketplace
for human biospecimens
2022 Annual Report


450 Bedford Street | Lexington, MA 02420 | 781-301-6700
Dear Fellow Stockholders,
It is an exciting time to be associated with iSpecimen.
In September 2022, iSpecimen commenced on a strategic corporate review and predictive revenue
realignment in resources. We have been making meaningful progress towards understanding and tapping
into the full potential of our entire organization. Our efforts have yielded results, as evidenced by our recordbreaking revenue in Q4 2022 of $3.2 million, a 28% increase over Q4 2021.
For 2023, in addition to our core business and as part of a very deliberately developed strategic plan, we
are undertaking several revenue enhancement projects in areas such as sequencing, remnants, and normal
blood, as well as the acceleration of on-site iSpecimen project coordinators at selected suppliers    sites to
facilitate improved specimen feasibility, identification, coordination, utilization, and fulfillment. iSpecimen
plans to continue to invest, where necessary, throughout 2023, to accelerate these revenue growth
initiatives.
We plan to make a significant portion of our investment in technology for the 2023 fiscal year, during the
first half of the year. We believe that this demonstrates our commitment to our vision to be transformational
in our industry with our online marketplace. Our technology efforts to improve the iSpecimen marketplace
platform in 2023 will include updating search functionality, improving the user interface, increasing
automation, and enhancing matchmaking. I   m pleased to report that, as of the date of this letter, all of these
efforts remain on track. To complete these updates, we are leveraging our significant technology
investments to date in our data processing and pipelines.
Executing these plans is critical to the success of iSpecimen. It is important that we execute iSpecimen   s
mission to accelerate life science research and development via a single global marketplace platform that
connects researchers to subjects, specimens, and data. To do so, we will expend all of our efforts to ensure
that our marketplace platform provides a comprehensive solution with ease of use so that researchers are
able to search for desired biospecimens, suppliers can fully utilize their biospecimens, and additional
adjacent opportunities can be unlocked for us. As we move forward, all of our activities, initiatives, and
projects in 2023 are focused on this mission.
I would like to extend my deepest gratitude to the entire iSpecimen team for their dedication, hard work,
and belief in our collective vision. The team   s continued support and efforts inspire me as we make progress
executing on our strategic plans and key initiatives for 2023.
Regards,
Tracy Curley
Chief Executive Officer

4/10/2023 Letter Continued (Full PDF)

 

Nothing in StockholderLetter.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy.